Design Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Design Therapeutics

14/08/2023 22:05

* Design Therapeutics Inc  DSGN.OQ  reported a quarterly
adjusted
loss of 36 cents​​ per share for the quarter ended in June. The
mean expectation of four analysts for the quarter was for a loss
of 40 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Design Therapeutics Inc's reported EPS for the quarter was
a
loss of 36 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Design Therapeutics Inc shares had risen by 21.9% this
quarter and lost 25.1% so far this year.
    * The company reported a quarterly loss of $19.94 million.
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $22.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 09:04 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.40          -0.36          Beat
 Mar. 31 2023      -0.36          -0.35          Beat
 Dec. 31 2022      -0.34          -0.31          Beat
 Sep. 30 2022      -0.29          -0.32          Missed